Join us at EACR-AACR-IACR Basic and Translational Research Conference
1/27/24
1/29/24
Offline
Dublin, Ireland
Share
MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.
MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.
MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.
MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.
Introduction
The European Association for Cancer Research (EACR) and American Association for Cancer Research (AACR) are proud to continue their Basic and Translational Research Conference series with this new joint conference in Dublin, Ireland in collaboration with the Irish Association for Cancer Research (IACR).
Gathering top experts in the fields of immunology, drug development, tumour microenvironment, genomics and epigenetics, this Joint Conference will focus on bringing the latest discoveries from basic science to the clinic. The forum will highlight the latest cutting-edge advances in the understanding of the genomics, epigenetics and molecular pathways involved in the development of pre-cancerous and cancerous lesions and/ or in cancer response to therapy. The scientific programme blends basic and translational research from preclinical models to patients.
Background
Cancer is caused by a complex interaction between inherited genetics, acquired somatic mutations, epigenetic changes and environmental factors. Genetic and epigenetic changes alter the competitive fitness of normal, stem and/ or progenitor cells giving them the ability to grow uncontrollably and spread. However, cancers develop in complex tissue environments, which they depend upon for progression and metastasis and cancer development is further modulated by the immune response. Understanding how reciprocal communication between cancer cells, the immune and stromal cells controls tumour development and modulates the response to therapeutic intervention is key for progressing cancer care. Moreover, a series of new, exciting studies have recently investigated the effects of conventional chemotherapy and immunotherapy uncovering unanticipated additional modes of action and unforeseen cellular effects. Altogether this opens novel opportunities for mechanism-based combinations, the discovery of novel drug targets and the development of new drugs.
Target Audience
The target audience for this conference is basic and translational scientists, including experienced investigators and trainees at all levels with an interest in cancer development and treatment, as well as clinicians involved in the development of novel therapeutic approaches to treatment.
MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.
Introduction
The European Association for Cancer Research (EACR) and American Association for Cancer Research (AACR) are proud to continue their Basic and Translational Research Conference series with this new joint conference in Dublin, Ireland in collaboration with the Irish Association for Cancer Research (IACR).
Gathering top experts in the fields of immunology, drug development, tumour microenvironment, genomics and epigenetics, this Joint Conference will focus on bringing the latest discoveries from basic science to the clinic. The forum will highlight the latest cutting-edge advances in the understanding of the genomics, epigenetics and molecular pathways involved in the development of pre-cancerous and cancerous lesions and/ or in cancer response to therapy. The scientific programme blends basic and translational research from preclinical models to patients.
Background
Cancer is caused by a complex interaction between inherited genetics, acquired somatic mutations, epigenetic changes and environmental factors. Genetic and epigenetic changes alter the competitive fitness of normal, stem and/ or progenitor cells giving them the ability to grow uncontrollably and spread. However, cancers develop in complex tissue environments, which they depend upon for progression and metastasis and cancer development is further modulated by the immune response. Understanding how reciprocal communication between cancer cells, the immune and stromal cells controls tumour development and modulates the response to therapeutic intervention is key for progressing cancer care. Moreover, a series of new, exciting studies have recently investigated the effects of conventional chemotherapy and immunotherapy uncovering unanticipated additional modes of action and unforeseen cellular effects. Altogether this opens novel opportunities for mechanism-based combinations, the discovery of novel drug targets and the development of new drugs.
Target Audience
The target audience for this conference is basic and translational scientists, including experienced investigators and trainees at all levels with an interest in cancer development and treatment, as well as clinicians involved in the development of novel therapeutic approaches to treatment.
MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.
Introduction
The European Association for Cancer Research (EACR) and American Association for Cancer Research (AACR) are proud to continue their Basic and Translational Research Conference series with this new joint conference in Dublin, Ireland in collaboration with the Irish Association for Cancer Research (IACR).
Gathering top experts in the fields of immunology, drug development, tumour microenvironment, genomics and epigenetics, this Joint Conference will focus on bringing the latest discoveries from basic science to the clinic. The forum will highlight the latest cutting-edge advances in the understanding of the genomics, epigenetics and molecular pathways involved in the development of pre-cancerous and cancerous lesions and/ or in cancer response to therapy. The scientific programme blends basic and translational research from preclinical models to patients.
Background
Cancer is caused by a complex interaction between inherited genetics, acquired somatic mutations, epigenetic changes and environmental factors. Genetic and epigenetic changes alter the competitive fitness of normal, stem and/ or progenitor cells giving them the ability to grow uncontrollably and spread. However, cancers develop in complex tissue environments, which they depend upon for progression and metastasis and cancer development is further modulated by the immune response. Understanding how reciprocal communication between cancer cells, the immune and stromal cells controls tumour development and modulates the response to therapeutic intervention is key for progressing cancer care. Moreover, a series of new, exciting studies have recently investigated the effects of conventional chemotherapy and immunotherapy uncovering unanticipated additional modes of action and unforeseen cellular effects. Altogether this opens novel opportunities for mechanism-based combinations, the discovery of novel drug targets and the development of new drugs.
Target Audience
The target audience for this conference is basic and translational scientists, including experienced investigators and trainees at all levels with an interest in cancer development and treatment, as well as clinicians involved in the development of novel therapeutic approaches to treatment.
MGI Tech is thrilled to announce its participation in the upcoming EACR-AACR-IACR Basic and Translational Research Conference, taking place on 27-29 February. We're eager to connect with fellow researchers, scientists, and professionals who share our passion for advancing basic science discoveries to the clinic at Booth 5.
Introduction
The European Association for Cancer Research (EACR) and American Association for Cancer Research (AACR) are proud to continue their Basic and Translational Research Conference series with this new joint conference in Dublin, Ireland in collaboration with the Irish Association for Cancer Research (IACR).
Gathering top experts in the fields of immunology, drug development, tumour microenvironment, genomics and epigenetics, this Joint Conference will focus on bringing the latest discoveries from basic science to the clinic. The forum will highlight the latest cutting-edge advances in the understanding of the genomics, epigenetics and molecular pathways involved in the development of pre-cancerous and cancerous lesions and/ or in cancer response to therapy. The scientific programme blends basic and translational research from preclinical models to patients.
Background
Cancer is caused by a complex interaction between inherited genetics, acquired somatic mutations, epigenetic changes and environmental factors. Genetic and epigenetic changes alter the competitive fitness of normal, stem and/ or progenitor cells giving them the ability to grow uncontrollably and spread. However, cancers develop in complex tissue environments, which they depend upon for progression and metastasis and cancer development is further modulated by the immune response. Understanding how reciprocal communication between cancer cells, the immune and stromal cells controls tumour development and modulates the response to therapeutic intervention is key for progressing cancer care. Moreover, a series of new, exciting studies have recently investigated the effects of conventional chemotherapy and immunotherapy uncovering unanticipated additional modes of action and unforeseen cellular effects. Altogether this opens novel opportunities for mechanism-based combinations, the discovery of novel drug targets and the development of new drugs.
Target Audience
The target audience for this conference is basic and translational scientists, including experienced investigators and trainees at all levels with an interest in cancer development and treatment, as well as clinicians involved in the development of novel therapeutic approaches to treatment.
Topics to be covered:
Immunotherapy / Immuno-Oncology
Cell-Based Therapies
Novel Targets / Undruggable Targets
Drug Combinations
Drug Resistance
The Precancer Genome
Liquid Biopsies
Preclinical Models
Tumour Microenvironment
Epigenetics
EACRAACRIACR2024
Science To Clinic
Rsearch Innovation
Events
EARC
Share this article :
Share
Sep 10, 2024
MGI Tech Unveils its SEQ ALL landscape at the Future of Omics Conference
Discover insights from the "Future of Omics" event, where leading experts discussed innovations in genomics, proteomics, and metabolomics. Explore key takeaways on advancing research and technology, shaping the future of personalized medicine and healthcare. Join us in celebrating the progress in omics!
Jun 1, 2024
MGI Tech Shares New Data on Core DNEBSEQ Technology and Showcases Latest Sequencing Innovations at ESHG 2024
MGI showcased its latest innovations at the ESHG 2024, highlighting the upgraded StandardMPS 2.0 sequencing chemistry and unveiling the new DNBelab C-TaiM 4 Single-Cell Droplet Generator. European researchers presented advancements in diagnostics, population health, and more.
Apr 27, 2024
MGI Showcases New DNBSEQ-E25 Sequencer & Partners with ABL Diagnostics at ESCMID Global 2024
MGI introduced its portable DNBSEQ-E25 sequencer at ESCMID Global 2024, designed for mobile and efficient genomic sequencing with applications in infectious diseases. Additionally, MGI announced a partnership with ABL Diagnostics to integrate DeepChek® assays into its platforms, broadening NGS solutions for microbiology labs.
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).